Dergiler / Uluslararası Hematoloji-Onkoloji Dergisi / 2020 / Cilt: 30 - Sayı: 4

Single Center Experience on Screening Oncology Patients for Covid-19 Before Anti-Cancer Treatment

Sayfa
207–212
DOI
—
🏛️Bu makalenin bibliyografik verileri ve tam metin bağlantısı DergiPark üzerinden sağlanmıştır.
DergiPark Kaydı ↗
✨

Yapay Zeka Hızlı Bakış & Çıkarımlar

AI Insight
⚡ TL;DR(1 Cümlede Hızlı Çıkarım)

Covid-19 testing before anti-cancer treatment may be recommended in order to continue their treatment without any problems and to prevent the risk of transmission due to the high rate of asymptomatics in infected patients.

📌 3 Maddede Bu Makale

🎯
Amaç & Hipotez:The most important factor in the transmission of the COVID-19 is asymptomatic carriers.
📊
Temel Bulgular & Veri:We’ve tested all oncology patients , that receive anti-cancer therapy, for COVID-19.
💡
Sonuç & Katkı:Covid-19 testing before anti-cancer treatment may be recommended in order to continue their treatment without any problems and to prevent the risk of transmission due to the high rate of asymptomatics in infected patients.
🔬Tür:Araştırma Makalesi
📍Kapsam:Genişletilmiş Akademik Örneklem
⚙️Değişkenler:Alan Parametreleri

Özet

The most important factor in the transmission of the COVID-19 is asymptomatic carriers. We’ve tested all oncology patients , that receive anti-cancer therapy, for COVID-19. We aimed to determine the rate of asymptomatic carriers, and analyze the clinical and ra-diological findings of infected patients. Oncology patients who have indications of receiving anti-cancer treatment in the hospital were tested for COVID-19, two day prior to their treatment even if they were asymptomatic by collecting nasopharyngeal and oropharyngeal swab specimens for RT-PCR for viral RNA detection. Positive patients, underwent inspiratory phase of chest computed tomography examination. Infected patients were given the recommended treatment for COVID-19. PCR test was positive in 28 of 312 patients that we tested, and the positivity rate was 8.9%. Three patients (10.7%) had symptoms, 25 patients (89.3%) had no symptoms. Covid-19 testing before anti-cancer treatment may be recommended in order to continue their treatment without any problems and to prevent the risk of transmission due to the high rate of asymptomatics in infected patients.

🔖

Bu Makaleye Atıf Yap

NAMAL, E., DİNÇ, M. N., SAGLAM, S., OZTURK, A. V., DEMIR, S. K., YIR, A., ÇEVİK, Ö. E., SABET, S., SOKMEN, B. K., GURCAN, N. I., TOKAT, Y., ÇİFTÇİ, C. (2020). Single Center Experience on Screening Oncology Patients for Covid-19 Before Anti-Cancer Treatment. Uluslararası Hematoloji-Onkoloji Dergisi, Cilt: 30 - Sayı: 4, 207–212. https://ajindex.com/articles/322727

📄 Tam Metin PDF Okuyucu

📄

PDF görüntüleyici hazırlanıyor...

Kaynakça (1)

  1. Surveillance case definitions for human infection with novel coronavirus (nCoV) Interim guidance v2 15 January 2020 WHO/2019-nCoV/Surveillance/v2020.2 2.World Health Organization. Director-General’s remarks at the media briefing on 2019-nCoV on 11 February 2020. https://www.who.int/dg/speeches/detail/who-director-general-s-remarks-at-the-media-briefing-on-2019-ncov-on-11-febru-ary-2020 Accessed on February 12, 2020. 3.World Health Organization. Coronavirus disease (COVID-19) Pandemic. www.who.int/emergencies/diseases/novel-coro-navirus-2019. 4.Perrotta F, Corbi G, Mazzeo G, et al. COVID-19 and the el-derly: insights into pathogenesis and clinical decision-making. Aging Clin Exp Res 32: 1599-1608, 2020. 5.World Health Organization. Modes-of-transmission-of-virus-causing-covid-19-implications-for-ipc-precaution-recom-mendations. www.who.int/news-room/commentaries/detail/modes-of-transmission-of-virus-causing-covid-19-implica-tions-for-ipc-precaution-recommendations. 6.Onder G, Rezza G, Brusaferro S. Case-fatality rate and char-acteristics of patients dying in relation to COVID-19 in Italy. JAMA 323: 1775-1776, 2020. 7.Liang W, Guan W, Chen R, et al. Cancer patients in SARS-CoV-2 infection: a nationwide analysis in China. Lancet Oncol 213: 335-337, 2020. 8.General Information about COVID-19 & Cancer. https://www.asco.org/asco-coronavirus-resources/care-individuals-cancer-during-covid-19/general-information-about-covid-19. 9.COVID-19 Pandemisinde Hekimlerin Almalari Gereken Kisi-sel Onlemler. https://www.kanser.org/saglik/haberler/covid-19-pandemisinde-hekimlerin-almalari-gereken-kisisel-onlem-ler/2129. 10.European Society of Medical Oncology. Cancer patient man-agement during the COVID-19 pandemic. European Soci-ety of Medical Oncology Web Site. https://www.esmo.org/guidelines/cancer-patient-management-during-the-covid-19-pandemic. 2020. Accessed April 17, 2020. 11.Infectious Diseases Society of America Guidelines on the Diagnosis of COVID-19. https://www.idsociety.org/practice-guideline/covid-19-guideline-diagnostics/ Accessed on May 08, 2020. 12.Chan JF, Yuan S, Kok KH, et al. A familial cluster of pneu-monia associated with the 2019 novel coronavirus indicating person-to-person transmission: a study of a family cluster. Lancet 395: 514-23, 2020. 13.https://www.who.int/docs/default-source/coronavi-ruse/situation-reports/20200124-sitrep-4-2019-ncov.pdf?sfvrsn=9272d086_8 14.Mizumoto K, Kagaya K, Zarebski A, Chowell G. Estimating the asymptomatic proportion